Patents by Inventor Cosimo Dolente
Cosimo Dolente has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12116349Abstract: The invention provides a novel compound having the general formula (I) or a pharmaceutically acceptable salt thereof. The compound of formula (I) can be used as a medicament.Type: GrantFiled: June 8, 2022Date of Patent: October 15, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Francesco Tommaso Pettazzoni, Juergen Wichmann
-
Publication number: 20240199581Abstract: The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.Type: ApplicationFiled: December 8, 2023Publication date: June 20, 2024Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveshuk, Katrina L. Jackson, Yanke Liang, Robert T. Yu, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Morgan Welzel O'Shea, Gesine Kerstin Veits, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Franceso Tommaso Pettazzoni, Juergen Wichmann
-
Publication number: 20240174621Abstract: The invention provides, for example, a novel compound having the general formula (I): or a pharmaceutically acceptable salt thereof. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: November 30, 2023Publication date: May 30, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, David Stephen HEWINGS, Daniel HUNZIKER, Daniela KRUMMENACHER, Piergiorgio Francesco Tommaso PETTAZZONI, Juergen WICHMANN
-
Publication number: 20240059692Abstract: The invention provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as described herein. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: November 29, 2021Publication date: February 22, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Ulrike OBST SANDER, Antonio RICCI
-
Publication number: 20240018154Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R4 and A are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: November 29, 2021Publication date: January 18, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Christa Ulrike OBST-SANDER, Antonio RICCI
-
Publication number: 20240018163Abstract: The invention relates to a compound of formula (I) wherein R1—R4 and A1-A3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: September 15, 2023Publication date: January 18, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Virginie BROM, Cosimo DOLENTE, Delphine GAUFRETEAU, Nadine GRETHER, Fionn Susannah O'HARA, Matilde PIRAS, Hasane RATNI, Michael REUTLINGER, Walter VIFIAN, Claudio ZAMBALDO
-
Publication number: 20240010659Abstract: The invention relates to a compound of formula (I) wherein R1-R4 and A1 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: September 15, 2023Publication date: January 11, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Nadine GRETHER, Fionn Susannah O'HARA, Matilde PIRAS, Hasane RATNI, Michael REUTLINGER, Walter VIFIAN, Claudio ZAMBALDO
-
Publication number: 20240002390Abstract: The invention provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R2?, R3, R4 and R5 are as described herein. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: November 29, 2021Publication date: January 4, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Ulrike OBST SANDER, Antonio RICCI
-
Publication number: 20240002407Abstract: The invention relates to a compound of formula (I) wherein X, R1-R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: September 15, 2023Publication date: January 4, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Nadine GRETHER, Fionn Susannah O'HARA, Matilde PIRAS, Hasane RATNI, Michael REUTLINGER, Walter VIFIAN, Claudio ZAMBALDO
-
Publication number: 20230331682Abstract: The invention relates to a compound of formula (I) Wherein A, L, R1, R2, R3 and R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: June 16, 2023Publication date: October 19, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
-
Publication number: 20230322776Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: June 16, 2023Publication date: October 12, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Erik Jung, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
-
Publication number: 20230202990Abstract: The invention provides novel compounds having the general formula I wherein R1, R2 and R3 are as defined herein, compositions including the compounds and methods of using the compounds as V1a receptor modulators for treatment of conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior, social anxiety disorder, post-traumatic stress disorder (PTSD), brain edema in stroke or traumatic brain injury, and phase shift sleep disorders such as jetlagType: ApplicationFiled: January 20, 2023Publication date: June 29, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Guido GALLEY, Patrick SCHNIDER
-
Publication number: 20230145336Abstract: Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.Type: ApplicationFiled: December 19, 2022Publication date: May 11, 2023Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Katrina L. Jackson, Yanke Liang, Moses Moustakim, Morgan Welzel O'Shea, Gesine Kerstin Veits, Jeremy L. Yap, Robert T. Yu, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Bernd Kuhn, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
-
Publication number: 20230106150Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.Type: ApplicationFiled: November 29, 2022Publication date: April 6, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Valerie Runtz-Schmitt, Patrick Schnider, Cosimo Dolente, Bernhard Fasching
-
Publication number: 20230054473Abstract: The application relates to (106) specific heterocyclic compounds comprising a thiazole ring, an indazol and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole system, to pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: February 23, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Patent number: 11578077Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.Type: GrantFiled: October 8, 2019Date of Patent: February 14, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Valerie Runtz-Schmitt, Patrick Schnider, Cosimo Dolente, Bernhard Fasching
-
Publication number: 20220315591Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Roger David NORCROSS, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315593Abstract: The application relates to 6 specific heterocyclic compounds, pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220315592Abstract: The application relates to a compound of formula (I) containing a thiazole ring, an indazol ring and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole ring system, to pharmaceutical compositions containing it and its medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.Type: ApplicationFiled: June 19, 2020Publication date: October 6, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
-
Publication number: 20220298145Abstract: The invention provides a novel compound having the general formula (I) wherein R1-R3 and X are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: June 8, 2022Publication date: September 22, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, David Stephen HEWINGS, Daniel HUNZIKER, Daniela KRUMMENACHER, Piergiorgio Francesco Tommaso PETTAZZONI, Juergen WICHMANN